SCP Vitalife

About

Portfolio · 5

Trig Medical

Ultrasound Tracking and Monitoring Solutions for Childbirth

1 round $4.1M committed Latest: 2009-08

novoGi

GI Disease Management

1 round $18.5M committed Latest: 2009-08

POCARED Diagnostics

Automated, Reagent-free Microorganism Detection

1 round $10.7M committed Latest: 2007-06

Beta-O2 Technologies

Implantable Bioreactor for Treating Type 1 Diabetes

1 round $2.0M committed Latest: 2004-03

GeneGrafts

Cell Therapy for Modulating Excitable Tissues

1 round Latest: 2003-12

Investment activity

3 portfolio exits on record.

Q&A

What is SCP Vitalife's investment focus?

SCP Vitalife is a venture capital firm that focuses on life sciences investments in Israel and the United States, targeting early to mid-stage companies with exceptional technologies.

What is SCP Vitalife's typical initial investment size?

SCP Vitalife's target initial investment size is between $3 million and $7 million, with a typical total investment of $7 million to $15 million over the lifespan of an investment.

Which sectors does SCP Vitalife primarily invest in?

SCP Vitalife primarily invests in the Health Tech & Life Sciences sector, with all of its portfolio companies and exits concentrated in this area.

Can you name a notable exit for SCP Vitalife in recent years?

In September 2018, SCP Vitalife saw an exit with MST - Medical Surgery Technologies, which was acquired by Asensus for $34 million.

What is SCP Vitalife's geographic investment strategy?

SCP Vitalife allocates over half of its investment capital to Israeli companies or companies with significant R&D and operational ties to Israel, with the remainder going to companies based in the United States.

Who is a key team member at SCP Vitalife?

Jeff Dykan is a Managing Partner at SCP Vitalife.

What is one of SCP Vitalife's portfolio companies that went public?

SCP Vitalife has a portfolio company, Lifeward, which went public on NASDAQ in September 2014 with a valuation of $136 million.

What is another public exit for SCP Vitalife?

Regentis Biomaterials, a portfolio company of SCP Vitalife, is expected to have a public offering on NASDAQ in September 2025.